Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions.
Liu Y, Zhang X, Liu J, Xia H, Zou J, Muruato AE, Periasamy S, Kurhade C, Plante JA, Bopp NE, Kalveram B, Bukreyev A, Ren P, Wang T, Menachery VD, Plante KS, Xie X, Weaver SC, Shi PY. Liu Y, et al. Among authors: bukreyev a. Nat Commun. 2022 Jul 27;13(1):4337. doi: 10.1038/s41467-022-31930-z. Nat Commun. 2022. PMID: 35896528 Free PMC article.
Topoisomerase III-ß is required for efficient replication of positive-sense RNA viruses.
Prasanth KR, Hirano M, Fagg WS, McAnarney ET, Shan C, Xie X, Hage A, Pietzsch CA, Bukreyev A, Rajsbaum R, Shi PY, Bedford MT, Bradrick SS, Menachery V, Garcia-Blanco MA. Prasanth KR, et al. Among authors: bukreyev a. bioRxiv [Preprint]. 2020 Mar 27:2020.03.24.005900. doi: 10.1101/2020.03.24.005900. bioRxiv. 2020. Update in: Antiviral Res. 2020 Oct;182:104874. doi: 10.1016/j.antiviral.2020.104874 PMID: 32511318 Free PMC article. Updated. Preprint.
Topoisomerase III-β is required for efficient replication of positive-sense RNA viruses.
Prasanth KR, Hirano M, Fagg WS, McAnarney ET, Shan C, Xie X, Hage A, Pietzsch CA, Bukreyev A, Rajsbaum R, Shi PY, Bedford MT, Bradrick SS, Menachery V, Garcia-Blanco MA. Prasanth KR, et al. Among authors: bukreyev a. Antiviral Res. 2020 Oct;182:104874. doi: 10.1016/j.antiviral.2020.104874. Epub 2020 Jul 28. Antiviral Res. 2020. PMID: 32735900 Free PMC article.
Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022.
Atyeo C, Slein MD, Fischinger S, Burke J, Schäfer A, Leist SR, Kuzmina NA, Mire C, Honko A, Johnson R, Storm N, Bernett M, Tong P, Zuo T, Lin J, Zuiani A, Linde C, Suscovich T, Wesemann DR, Griffiths A, Desjarlais JR, Juelg BD, Goudsmit J, Bukreyev A, Baric R, Alter G. Atyeo C, et al. Among authors: bukreyev a. JCI Insight. 2021 Jan 11;6(1):e143129. doi: 10.1172/jci.insight.143129. JCI Insight. 2021. PMID: 33427208 Free PMC article.
mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge.
Meyer M, Wang Y, Edwards D, Smith GR, Rubenstein AB, Ramanathan P, Mire CE, Pietzsch C, Chen X, Ge Y, Cheng WS, Henry C, Woods A, Ma L, Stewart-Jones GBE, Bock KW, Minai M, Nagata BM, Periasamy S, Shi PY, Graham BS, Moore IN, Ramos I, Troyanskaya OG, Zaslavsky E, Carfi A, Sealfon SC, Bukreyev A. Meyer M, et al. Among authors: bukreyev a. bioRxiv [Preprint]. 2021 Jan 25:2021.01.25.428136. doi: 10.1101/2021.01.25.428136. bioRxiv. 2021. Update in: J Clin Invest. 2021 Oct 15;131(20):e148036. doi: 10.1172/JCI148036 PMID: 33532780 Free PMC article. Updated. Preprint.
A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19.
Malherbe DC, Kurup D, Wirblich C, Ronk AJ, Mire C, Kuzmina N, Shaik N, Periasamy S, Hyde MA, Williams JM, Shi PY, Schnell MJ, Bukreyev A. Malherbe DC, et al. Among authors: bukreyev a. NPJ Vaccines. 2021 Jul 22;6(1):91. doi: 10.1038/s41541-021-00352-1. NPJ Vaccines. 2021. PMID: 34294728 Free PMC article.
Attenuated activation of pulmonary immune cells in mRNA-1273-vaccinated hamsters after SARS-CoV-2 infection.
Meyer M, Wang Y, Edwards D, Smith GR, Rubenstein AB, Ramanathan P, Mire CE, Pietzsch C, Chen X, Ge Y, Cheng WS, Henry C, Woods A, Ma L, Stewart-Jones GB, Bock KW, Minai M, Nagata BM, Periasamy S, Shi PY, Graham BS, Moore IN, Ramos I, Troyanskaya OG, Zaslavsky E, Carfi A, Sealfon SC, Bukreyev A. Meyer M, et al. Among authors: bukreyev a. J Clin Invest. 2021 Oct 15;131(20):e148036. doi: 10.1172/JCI148036. J Clin Invest. 2021. PMID: 34449440 Free PMC article.
Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition.
Kramer KJ, Johnson NV, Shiakolas AR, Suryadevara N, Periasamy S, Raju N, Williams JK, Wrapp D, Zost SJ, Walker LM, Wall SC, Holt CM, Hsieh CL, Sutton RE, Paulo A, Nargi RS, Davidson E, Doranz BJ, Crowe JE Jr, Bukreyev A, Carnahan RH, McLellan JS, Georgiev IS. Kramer KJ, et al. Among authors: bukreyev a. Cell Rep. 2021 Oct 5;37(1):109784. doi: 10.1016/j.celrep.2021.109784. Epub 2021 Sep 16. Cell Rep. 2021. PMID: 34592170 Free PMC article.
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.
Maisonnasse P, Aldon Y, Marc A, Marlin R, Dereuddre-Bosquet N, Kuzmina NA, Freyn AW, Snitselaar JL, Gonçalves A, Caniels TG, Burger JA, Poniman M, Bontjer I, Chesnais V, Diry S, Iershov A, Ronk AJ, Jangra S, Rathnasinghe R, Brouwer PJM, Bijl TPL, van Schooten J, Brinkkemper M, Liu H, Yuan M, Mire CE, van Breemen MJ, Contreras V, Naninck T, Lemaître J, Kahlaoui N, Relouzat F, Chapon C, Ho Tsong Fang R, McDanal C, Osei-Twum M, St-Amant N, Gagnon L, Montefiori DC, Wilson IA, Ginoux E, de Bree GJ, García-Sastre A, Schotsaert M, Coughlan L, Bukreyev A, van der Werf S, Guedj J, Sanders RW, van Gils MJ, Le Grand R. Maisonnasse P, et al. Among authors: bukreyev a. Nat Commun. 2021 Oct 20;12(1):6097. doi: 10.1038/s41467-021-26354-0. Nat Commun. 2021. PMID: 34671037 Free PMC article.
194 results